EWSR1 and neoplasm: Genomic fusion sequences are considered highly specific tumor markers in leukemic diseases and EWS patients; however, several fusion genes (e.g., CIC-DUX in Ewing-like sarcoma and BCR-ABL1 in Ph+ALL patients) have unfavorable genetic structures for the establishment of high-sensitivity quantification assays.